Further reduction of outstanding debt by Madryn Asset Management improves the Company’s balance sheet positionTORONTO, July 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that, on June 30, 2025, the Company exchanged $6.5 million of its subordinated convertible notes held by affiliates of Madryn Asset Management, LP (“Madryn”) for 325,651 shares of its Series Y preferred stock. Following the tra ...

$1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrantsTORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 434,720 shares of common stock at a purcha ...

$1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrantsTORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share in a registered direct offering ...

交易概述 - Venus Concept宣布以2000万美元现金出售其Venus Hair业务给Meta Healthcare Group [1] - 交易预计在2025年第三季度完成 需满足包括内部重组在内的交割条件 [3] - 交易净收益将用于改善公司资产负债表 并为战略增长计划提供资金 [1] 交易细节 - Meta Healthcare Group将收购Venus Concept新成立的子公司Meta Robotics LLC 包括头发修复和移植技术组合 相关设备 服务及资产 [2] - Meta Healthcare Group将授予Venus Concept部分转让专利的永久免版税全球许可 [2] - Meta Healthcare Group将接管Venus Concept位于加州圣何塞的研发制造设施 并获得NeoGraft的生产权 [2] 财务数据 - Venus Hair业务2024财年收入约为1250万美元 来自ARTAS和NeoGraft系统 手术套件及保修收入 [3] - Venus Concept头发修复和移植业务2024财年运营现金使用量约为670万美元 [3] 战略意义 - Venus Concept表示交易有助于公司专注于全球医美业务 预计将提高收入增长 降低运营成本 改善现金流 加速长期可持续盈利 [2] - Meta Healthcare Group认为收购符合其扩大脱发相关业务领域的目标 包括脱发护理产品和植发手术设备 并将增强其研发和制造能力 [2] 公司背景 - Meta Healthcare Group成立于2021年2月 总部位于韩国首尔 是一家专注于医美领域的领先医疗科技公司 [5] - Meta Healthcare Group旗下拥有METAPHARM Co Ltd(医疗设备研发制造公司)和Techlabs Co Ltd(医疗营销平台提供商) [6] - Venus Concept是全球医美技术领导者 产品组合包括微创和非侵入性医美及头发修复技术 业务覆盖60多个国家和9个直销市场 [8] 交易顾问 - Canaccord Genuity担任Venus Concept的财务顾问 Dorsey & Whitney LLP担任法律顾问 [4] - Fredrikson & Byron PA担任Meta Healthcare Group的美国法律顾问 Bae Kim & Lee LLC担任韩国法律顾问 [4]

Venus Concept (VERO) Q1 2025 Earnings Call May 15, 2025 08:00 AM ET Company Participants Rajiv De Silva - Director & CEODomenic Della Penna - EVP & CFOThomas McGovern - Equity Research Associate Operator Good day, ladies and gentlemen, and welcome to the First Quarter twenty twenty five Earnings Conference Call for Venus Concept Inc. At this time, all participants have been placed in a listen only mode. Please note that this conference call is being recorded and that the recording will be available on the c ...

Venus Concept (VERO) Q1 2025 Earnings Call May 15, 2025 08:00 AM ET Speaker0 Good day, ladies and gentlemen, and welcome to the First Quarter twenty twenty five Earnings Conference Call for Venus Concept Inc. At this time, all participants have been placed in a listen only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay. Before we begin, I'd like to remind everyone that our remarks and responses to your questions toda ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-38238 Venus Concept Inc. Securities registered pursuant to Section 12(b) of the Act: ...

Exhibit 99.1 Venus Concept Announces First Quarter 2025 Financial Results TORONTO, May 15, 2025 (GLOBE NEWSWIRE) – Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2025. Summary of Financial Results & Recent Progress: Management Commentary: | | | | | Three Months Ended March 31, | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 2025 | | | | 2024 | | ...

| | Three Months Ended March 31, | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 2025 | | | 2024 | | | Change | | | | | | % of | | | | % of | | | | | | | (in thousands, except percentages) | | $ | Total | $ | Total | | $ | | % | | | Revenues by product: | | | | | | | | | | | | Venus Prime / Subscription—Systems | $ $ | 2,649 | 19.4 | 3,531 | | 20.2 $ | (882 | ) | (25.0 | ) | Total revenue for the first quarter of $13.6 million, down 22% year-over-year, reflecting ...

文章核心观点 公司宣布完成此前宣布的按纳斯达克规则以市价进行的普通股注册直接发行，两次发行总收益约270万美元，拟用于一般公司用途 [1][2] 发行情况 - 公司完成386,700股普通股注册直接发行，每股购买价4.06美元 [1] - H.C. Wainwright & Co.担任此次发行独家配售代理 [1] - 此次发行总收益约157万美元，此前4月10日发行总收益约115万美元，两次发行总收益约270万美元 [2] - 公司拟将发行所得净收益用于一般公司用途 [2] 发行依据 - 普通股依据2024年11月1日美国证券交易委员会生效的S - 3表格“暂搁”注册声明发售 [3] - 发行仅通过招股说明书进行，最终招股说明书补充文件及随附招股说明书已提交美国证券交易委员会 [3] 公司介绍 - 公司是全球医疗美容技术领先者，产品组合广泛，业务覆盖超60个国家和12个直接市场 [5] - 产品组合包括多种美容设备平台及毛发修复系统 [5] - 公司获多家医疗行业成长型股权投资者支持 [5] 联系方式 - 投资者关系联系人：ICR Westwicke代表公司的Mike Piccinino，邮箱VenusConceptIR@westwicke.com [7]